Very early treatment may be key to combatting inherited metabolic disorder

August 4, 2014
This image portrays representative images of GM3 (A–C), LIMP II (D–F), GFAP (G–I), isolectin Bandieraea (Griffonia) simplicifolia (BSI-B4) (J–L) and ubiquitin (M–O) staining in the inferior colliculus of 6-week-old normal (A, D, G, J and M), MPS IIIA (B, E, H, K and N) and MPS IIIA + enzyme-treated (C, F, I, L and O) mice. The rhSGSH injection was administered at 3 weeks of age and images were taken at 3 weeks post-injection, i.e. at 6 weeks of age. Scale bar: image, 50 μm; inset, 5 μm (A–O). Credit: Wiley

A European Journal of Neuroscience study suggests that it is critical to treat lysosomal storage disorders early, before symptoms arise. These genetic disorders, which are caused by the malfunction of enzymes that normally degrade various substances within cells, lead to numerous ailments including neurological problems.

Although few therapeutic options are available, clinical trials of treatments including lysosomal enzyme replacement are underway. Researchers who used enzyme replacement to treat mice with early, mid- and later-stages of a found that treatment was most effecting in mice with very early-stage disease. Once symptoms arose, treatment was ineffective.

"Until is available world-wide for these conditions, and children are diagnosed prior to symptoms appearing, it is critical that we continue to gather information regarding the reversibility, or not, of disease-based degenerative changes," said senior author Dr. Kim Hemsley.

Explore further: New therapy against rare gene defects

More information: Hassiotis, S., Beard, H., Luck, A., Trim, P. J., King, B., Snel, M. F., Hopwood, J. J. and Hemsley, K. M. (2014), Disease stage determines the efficacy of treatment of a paediatric neurodegenerative disease. European Journal of Neuroscience, 39: 2139–2150. DOI: 10.1111/ejn.12557

Related Stories

New therapy against rare gene defects

April 15, 2014

On 15th April is the 1st International Pompe Disease Day, a campaign to raise awareness of this rare but severe gene defect. Pompe Disease is only one of more than 40 metabolic disorders that mainly affect children under ...

Infant tests for debilitating diseases set for mainstream

April 2, 2013

(Medical Xpress)—Michael Gelb and František Tureček have worked more than a decade to devise and implement newborn screening for some debilitating, often-fatal conditions that show up in the first year to several years ...

Recommended for you

Scientists develop new drug screening tool for dystonia

December 8, 2016

Duke University researchers have identified a common mechanism underlying separate forms of dystonia, a family of brain disorders that cause involuntary, debilitating and often painful movements, including twists and turns ...

Transplanted interneurons can help reduce fear in mice

December 8, 2016

The expression "once bitten, twice shy" is an illustration of how a bad experience can induce fear and caution. How to effectively reduce the memory of aversive events is a fundamental question in neuroscience. Scientists ...

Honeybee memories: Another piece of the Alzheimer's puzzle?

December 8, 2016

A breakdown of memory processes in humans can lead to conditions such as Alzheimer's and dementia. By looking at the simpler brain of a honeybee, new research published in Frontiers in Molecular Neuroscience, moves us a step ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.